Home    Back

 114. Non-dystrophic myotonia syndrome
 [ 6 clinical trials,    5 drugs(DrugBank: 4 drugs),    18 target genes / 10 target pathways

Searched query = "Non dystrophic myotonia syndrome", "Non dystrophic Myotonia", "Myotonia congenita", "Paramyotonia congenita", "Thomsen disease", "Becker disease", "Sodium channel myotonia"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02251457August 201418 March 2019Study of Ranolazine in Myotonia Congenita, Paramyotonia Congenita and Myotonic Dystrophy Type 1Open Label Trial of Ranolazine in Myotonia Congenita, Paramyotonia Congenita, & Myotonic Dystrophy Type 1Myotonia Congenita;Paramyotonia Congenita;Myotonic Dystrophy 1Drug: RanolazineOhio State UniversityGilead SciencesNot recruiting18 Years100 YearsAll35Phase 1United States
2NCT01939561November 20132 May 2016Lamotrigine as Treatment of MyotoniaLamotrigine as Treatment of Myotonia - a Phase 3 Randomized Controlled Trial StudyDystrophia Myotonica Type 1;Myotonia Congenita;Paramyotonia Congenita;Hyperkalemic Periodic Paralysis;Potassium-Aggravated MyotoniaDrug: Lamotrigine;Drug: PlaceboGrete Andersen, MDNot recruiting18 YearsN/ABoth27Phase 3Denmark
3EUCTR2010-024026-38-NL10/01/201219 March 2012Combining N-of-1 trials to estimate population clinical effectiveness of drugs using Bayesian hierarchical modeling. The case of Mexilitin for patients with Non-Dystrophic Myotonia. - Mex vs. placebo in NDMsCombining N-of-1 trials to estimate population clinical effectiveness of drugs using Bayesian hierarchical modeling. The case of Mexilitin for patients with Non-Dystrophic Myotonia. - Mex vs. placebo in NDMsPatients with non-dystrophic myotonic syndromes (NDMs). NDMs are caused by mutations in the gene encoding for the skeletal muscle sodium (SCN4A) or chloride (CLCN1) channel. In this study patients with NDMs with a genetically confirmed mutation in the SCN4A-gene or the CLCN1-gene as registred in the Netherlands database of NDMs will be included.Trade Name: Mexitil
Product Name: mexitil
Pharmaceutical Form: Tablet
INN or Proposed INN: MEXILETINE
CAS Number: 31828714
Current Sponsor code: -
Other descriptive name: Mexitil
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 600 -
Pharmaceutical form of the placebo: Capsule*
Route of administration of the placebo: Oral use
Radboud University Nijmegen Medical CenterAuthorisedFemale: yes
Male: yes
30Netherlands
4NCT02336477June 201119 February 2015Mexiletine and Non Dystrophic MyotoniasEfficacy and Safety of Mexiletine in Non-dystrophic MyotoniasNon-dystrophic Myotonias;Paramyotonia Congenita;Myotonia CongenitaDrug: Mexiletine;Drug: placeboAssistance Publique - Hôpitaux de ParisNot recruiting18 Years65 YearsBoth24Phase 3France
5NCT00832000December 200819 October 2017Effectiveness of Mexiletine for Treating People With Non-Dystrophic MyotoniaPhase II Therapeutic Trial of Mexiletine in Non-Dystrophic MyotoniaMyotonia;Non-Dystrophic MyotoniaDrug: Mexiletine;Drug: PlaceboRichard Barohn, MDNot recruiting16 YearsN/AAll59Phase 2United States;Canada;Italy;United Kingdom
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00004802June 199219 February 2015Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dichlorphenamide for Periodic Paralyses and Associated Sodium Channel DisordersParalysis, Hyperkalemic Periodic;Hypokalemic Periodic Paralysis;Paramyotonia CongenitaDrug: dichlorphenamideNational Center for Research Resources (NCRR)Ohio State UniversityNot recruiting10 Years75 YearsBoth64Phase 3

Back to top